Financial
Latest full-year results from official filings.
FY2026 revenue A$51.6m (+27.0%); net margin 4.5%; net income A$2.3m.
Underlying EBITDA A$6.8m (+34%); A$20.6m cash, no debt.
- Official results release · Alcidion · 30 Jun 2026
Alcidion: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
No adverse media involving Alcidion found in HSH's search of the last 24 months.
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Alcidion found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Clinical software supplier (Miya Precision); no regulatory or clinical safety actions involving Alcidion found in HSH's search of the last 24 months.
Contract performance
Contract delivery, go-lives, terminations and disputes.
May 2026: North Cumbria Integrated Care went live with Alcidion's Miya Precision EPR after NHS England held back the planned March go-live; the trust said it had no significant local concerns. Jan 2026: University Hospitals Sussex selected Alcidion as EPR supplier.
- North Cumbria goes live with EPR following delay by NHSE · Digital Health · 1 May 2026
- University Hospitals Sussex selects Alcidion as EPR supplier · Digital Health · 1 Jan 2026